<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="777">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>9/09/2005</approvaldate>
  <nctid>NCT00168467</nctid>
  <trial_identification>
    <studytitle>The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease</studytitle>
    <scientifictitle>The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20/03</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Arterial Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ramipril

Treatment: drugs: Ramipril


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to onset of claudication</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Total exercise time during a standard treadmill test</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Walking ability measured using the standard Walking Impairment Questionnaire</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Leg Blood Flow using Duplex Ultrasound</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Ankle-brachial index of &lt;0.9 at rest in at least one leg

          -  History of intermittent claudication (unilateral or bilateral) which was stable for 6
             months

          -  Evidence of superficial femoral artery stenosis or occlusion on duplex scan

          -  Blood pressure &lt;=160/90 mmHg

          -  Stable medication regimen for at least 6 months and not previously treated with ACE
             inhibitors</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Limiting coronary artery disease

          -  Renal Failure

          -  History of hypertension

          -  History of type 2 diabetes mellitus</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Baker Heart Research Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>One important clinical challenge in older individuals is maintaining mobility in the absence
      of pain. Peripheral arterial disease affects up to 12% of adults over 50 and impairs quality
      of life due to intermittent claudication causing pain and limiting mobility.

      Conventional therapies have only modest effect in improving symptoms. The investigators
      hypothesise that angiotensin converting enzyme inhibition (with ramipril), which causes
      arterial vasodilation, also improves clinical symptoms in patients with peripheral arterial
      disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00168467</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bronwyn A Kingwell, PhD</name>
      <address>Baker Heart Research Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>